Raras
Buscar doenças, sintomas, genes...
Deficiência de proteína trifuncional mitocondrial
ORPHA:746CID-10 · G71.3CID-11 · 5C52.01DOENÇA RARA

A deficiência de proteína trifuncional mitocondrial (TFP) (TFPD) é um distúrbio da oxidação de ácidos graxos caracterizado por um amplo espectro clínico que varia de manifestações neonatais graves, incluindo cardiomiopatia, hipoglicemia, acidose metabólica, miopatia e neuropatia esquelética, doença hepática e morte, até um fenótipo leve com polineuropatia periférica, rabdomiólise episódica e retinopatia pigmentar.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A deficiência de proteína trifuncional mitocondrial (TFP) (TFPD) é um distúrbio da oxidação de ácidos graxos caracterizado por um amplo espectro clínico que varia de manifestações neonatais graves, incluindo cardiomiopatia, hipoglicemia, acidose metabólica, miopatia e neuropatia esquelética, doença hepática e morte, até um fenótipo leve com polineuropatia periférica, rabdomiólise episódica e retinopatia pigmentar.

Pesquisas ativas
1 ensaio
18 total registrados no ClinicalTrials.gov
Publicações científicas
82 artigos
Último publicado: 2026 Apr 8

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Casos conhecidos
100
pacientes catalogados
Início
Infancy
+ neonatal
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: G71.3
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

💪
Músculos
9 sintomas
🧠
Neurológico
8 sintomas
❤️
Coração
7 sintomas
📏
Crescimento
7 sintomas
🫃
Digestivo
4 sintomas
🦴
Ossos e articulações
3 sintomas

+ 31 sintomas em outras categorias

Características mais comuns

90%prev.
Intolerância ao exercício
Muito frequente (99-80%)
90%prev.
Rabdomiólise
Muito frequente (99-80%)
90%prev.
Arreflexia
Muito frequente (99-80%)
55%prev.
Insuficiência cardíaca congestiva
Frequente (79-30%)
55%prev.
Letargia
Frequente (79-30%)
55%prev.
Fraqueza muscular do membro inferior
Frequente (79-30%)
73sintomas
Muito frequente (3)
Frequente (20)
Ocasional (19)
Muito raro (4)
Sem dados (27)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 73 características clínicas mais associadas, ordenadas por frequência.

Intolerância ao exercícioExercise intolerance
Muito frequente (99-80%)90%
RabdomióliseRhabdomyolysis
Muito frequente (99-80%)90%
ArreflexiaAreflexia
Muito frequente (99-80%)90%
Insuficiência cardíaca congestivaCongestive heart failure
Frequente (79-30%)55%
LetargiaLethargy
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico82PubMed
Últimos 10 anos109publicações
Pico202214 papers
Linha do tempo
2026Hoje · 2026🧪 2006Primeiro ensaio clínico📈 2022Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

2 genes identificados com associação a esta condição. Padrão de herança: Autosomal recessive.

HADHBTrifunctional enzyme subunit beta, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial trifunctional enzyme catalyzes the last three of the four reactions of the mitochondrial beta-oxidation pathway (PubMed:29915090, PubMed:30850536, PubMed:8135828). The mitochondrial beta-oxidation pathway is the major energy-producing process in tissues and is performed through four consecutive reactions breaking down fatty acids into acetyl-CoA (PubMed:29915090). Among the enzymes involved in this pathway, the trifunctional enzyme exhibits specificity for long-chain fatty acids (P

LOCALIZAÇÃO

MitochondrionMitochondrion inner membraneMitochondrion outer membraneEndoplasmic reticulum

VIAS BIOLÓGICAS (8)
Acyl chain remodeling of CLBeta oxidation of hexanoyl-CoA to butanoyl-CoABeta oxidation of octanoyl-CoA to hexanoyl-CoABeta oxidation of decanoyl-CoA to octanoyl-CoA-CoABeta oxidation of lauroyl-CoA to decanoyl-CoA-CoA
MECANISMO DE DOENÇA

Mitochondrial trifunctional protein deficiency 2

An autosomal recessive metabolic disorder of long-chain fatty acid oxidation, biochemically characterized by loss of all enzyme activities of the mitochondrial trifunctional protein complex. The disease phenotype ranges from a fatal form characterized by early-onset cardiomyopathy, cardiac failure and early death to less severe, late-onset forms with myopathy, recurrent rhabdomyolysis, and sensorimotor axonal neuropathy as key features.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
375.3 TPM
Coração - Ventrículo esquerdo
307.5 TPM
Coração - Átrio
223.3 TPM
Glândula adrenal
186.5 TPM
Esôfago - Muscular
129.0 TPM
OUTRAS DOENÇAS (2)
mitochondrial trifunctional protein deficiency 2mitochondrial trifunctional protein deficiency
HGNC:4803UniProt:P55084
HADHATrifunctional enzyme subunit alpha, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial trifunctional enzyme catalyzes the last three of the four reactions of the mitochondrial beta-oxidation pathway (PubMed:1550553, PubMed:29915090, PubMed:30850536, PubMed:8135828, PubMed:31604922). The mitochondrial beta-oxidation pathway is the major energy-producing process in tissues and is performed through four consecutive reactions breaking down fatty acids into acetyl-CoA (PubMed:29915090). Among the enzymes involved in this pathway, the trifunctional enzyme exhibits specific

LOCALIZAÇÃO

MitochondrionMitochondrion inner membrane

VIAS BIOLÓGICAS (8)
Acyl chain remodeling of CLBeta oxidation of hexanoyl-CoA to butanoyl-CoABeta oxidation of octanoyl-CoA to hexanoyl-CoABeta oxidation of decanoyl-CoA to octanoyl-CoA-CoABeta oxidation of lauroyl-CoA to decanoyl-CoA-CoA
MECANISMO DE DOENÇA

Mitochondrial trifunctional protein deficiency 1

An autosomal recessive metabolic disorder of long-chain fatty acid oxidation, biochemically characterized by loss of all enzyme activities of the mitochondrial trifunctional protein complex. The disease phenotype ranges from a fatal form characterized by early-onset cardiomyopathy, cardiac failure and early death to less severe, late-onset forms with myopathy, recurrent rhabdomyolysis, and sensorimotor axonal neuropathy as key features.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
343.5 TPM
Coração - Ventrículo esquerdo
215.7 TPM
Linfócitos
203.7 TPM
Fibroblastos
194.0 TPM
Esôfago - Muscular
182.5 TPM
OUTRAS DOENÇAS (4)
long chain 3-hydroxyacyl-CoA dehydrogenase deficiencymitochondrial trifunctional protein deficiency 1mitochondrial trifunctional protein deficiencyacute fatty liver of pregnancy
HGNC:4801UniProt:P40939

Variantes genéticas (ClinVar)

470 variantes patogênicas registradas no ClinVar.

🧬 HADHB: NM_000183.3(HADHB):c.1177_1178insAA (p.Met393fs) ()
🧬 HADHB: NM_000183.3(HADHB):c.2_3insTAC (p.Met1delinsIleThr) ()
🧬 HADHB: NM_000183.3(HADHB):c.630+1G>A ()
🧬 HADHB: NM_000183.3(HADHB):c.349A>G (p.Arg117Gly) ()
🧬 HADHB: GRCh37/hg19 2p25.3-23.1(chr2:12771-30565600)x3 ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 1,431 variantes classificadas pelo ClinVar.

143
286
1002
Patogênica (10.0%)
VUS (20.0%)
Benigna (70.0%)
VARIANTES MAIS SIGNIFICATIVAS
HADHB: NM_000183.3(HADHB):c.1177_1178insAA (p.Met393fs) [Pathogenic]
HADHA: NM_000182.5(HADHA):c.314+2T>C [Likely pathogenic]
HADHA: NM_000182.5(HADHA):c.791T>G (p.Leu264Trp) [Uncertain significance]
HADHA: NM_000182.5(HADHA):c.17C>A (p.Ala6Glu) [Uncertain significance]
HADHA: NM_000182.5(HADHA):c.263C>T (p.Ala88Val) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 24
1Fase 11
·Pré-clínico5
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 10 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Deficiência de proteína trifuncional mitocondrial

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

18 ensaios clínicos encontrados, 1 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
49 papers (10 anos)
#1

Elamipretide Improves Mitochondrial Function in Mitochondrial Trifunctional Protein-Deficient Mice and Human Fibroblasts.

Journal of inherited metabolic disease2026 Jan

Mitochondrial trifunctional protein (TFP) deficiency is an inherited disorder of long-chain fatty acid β-oxidation (FAO). TFP is a heteromeric enzyme composed of two α and two β-subunits. Despite early detection and dietary treatment, TFP deficiency patients often develop hypoglycemia, rhabdomyolysis, cardiomyopathy, and peripheral neuropathy. Degenerative retinopathy and milder peripheral neuropathy occur in patients with an isolated deficiency of the αTFP subunit of long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) activity. Triheptanoin treatment improves most complications, but not peripheral neuropathy and retinopathy. Notably, TFP also carries a fourth enzymatic function involved in cardiolipin remodeling, which we previously found to be impaired in TFP/LCHAD deficiency. We therefore tested whether elamipretide, a synthetic cardiolipin-binding peptide, could improve mitochondrial function and cardiolipin levels in βTFP-deficient mice and patient-derived fibroblasts. Mice were treated with elamipretide delivered by osmotic minipump and challenged with treadmill exercise or cold stress after fasting. βTFP-deficient mice treated with elamipretide showed improved exercise endurance, but cold tolerance was not altered. Liver mitochondria from male βTFP-deficient mice demonstrated improved FAO-ETC enzyme activities. However, cardiolipin content and composition were unchanged. In patient fibroblasts, elamipretide produced a possible genotype-dependent increase in mitochondrial bioenergetics and a reduction in ROS. These results support a mechanism in which elamipretide stabilizes between FAO enzymes and ETC complexes, thereby improving mitochondrial function independently of changes in cardiolipin levels. Elamipretide thus emerges as a potential therapeutic agent for TFP/LCHAD deficiency, warranting further preclinical studies.

#2

Early-Onset Sensorimotor Axonal Neuropathy as Sole Manifestation of HADHA-Related Disorder/ Mitochondrial Trifunctional Protein Defect.

Journal of child neurology2026 Feb

Pathogenic variants in the HADHA and HADHB genes are associated with impairment of mitochondrial trifunctional protein. Mitochondrial trifunctional protein deficiency is a disorder of long-chain fatty acid oxidation with different clinical presentations: the neonatal-onset form expressing with severe cardiac phenotype, the infantile-onset form with intermediate hepatic phenotype with metabolic crises, and the late-onset form with mild neuromyopathic phenotype. Long-term complications in patients with the intermediate and late-onset phenotypes include peripheral neuropathy and retinopathy. We report a patient harboring 2 compound heterozygous variants in the HADHA gene (p.Tyr724* and p.Gly319Ser) and presenting with an early-onset, progressive sensorimotor axonal polyneuropathy, without any other systemic manifestations typical of mitochondrial trifunctional protein deficiency. We also provide a literature review of HADHA mutated patients presenting with early-onset isolated neuropathy phenotype.

#3

MR Neurography in Children and Adolescents: Multiparametric Assessment of Peripheral Nerve Involvement in Long-chain Fatty Acid Oxidation Disorders.

Investigative radiology2026 Feb 02

MR neurography (MRN) is a modern technique for visualizing peripheral nerves and quantifying microstructural pathology, yet its use in pediatric populations remains largely unexplored. This study evaluates the applicability and diagnostic performance of MRN in children and adolescents with genetically confirmed long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD) and mitochondrial trifunctional protein deficiency (MTPD), in which peripheral neuropathy is a known long-term complication. In a prospective cross-sectional study, 15 patients (LCHADD n = 6; MTPD n = 9) and 14 age-matched controls underwent high-resolution mid-thigh MRN of the sciatic nerve to assess (1) T2-based lesion burden for tibial (SNTib) and peroneal (SNPer) fascicles, (2) functional nerve integrity of the tibial fascicles using diffusion tensor metrics, including fractional anisotropy (FA) and radial diffusivity (RD), and (3) tibial fascicle-based T2 relaxometry parameters. In addition, clinical and electrophysiological data were obtained. Age-adjusted linear regression, ROC analyses, and linear discriminant analyses (LDA) quantified group effects and classification performance. Overall, patients showed higher T2 lesion burden compared with controls (SNTib: +2.75%, P = 0.001; SNPer: +1.94%, P = 0.001), reduced tibial fascicle FA (Δ: -0.098, P = 0.001), and increased tibial fascicle RD (Δ: +147.4×10-6 mm2/s, P = 0.011). Subgroup comparisons between LCHADD and MTPD revealed no significant differences. Of the 15 patients, 7 exhibited signs of clinical neuropathy. Neuropathic individuals showed pronounced abnormalities (SNTib: +4.22%, P < 0.001; SNPer: +2.29%, P = 0.002; ΔFA: -0.138, P < 0.001), while even those without clinical neuropathy exhibited elevated SNPer lesion burden (+1.64%; P = 0.018) and reduced tibial fascicle FA (Δ: -0.062, P = 0.03), compared with controls, indicating subclinical involvement. SNTib lesion burden showed excellent discrimination (AUC: 95.2%), and FA performed well (AUC: 81.2%). Multiparametric LDA achieved 93% apparent in-sample accuracy for patients versus controls, 86% for LCHADD versus MTPD, and 90% for classifying neuropathic, non-neuropathic, and control groups. MRN can be readily applied in children and adolescents and sensitively detects both clinically manifest and subclinical peripheral nerve involvement in long-chain fatty acid oxidation disorders. Extending this capability, exploratory LDA suggests that combining multiple MRN metrics may provide complementary diagnostic and phenotypic information beyond individual parameters.

#4

How Genes Meet Diet in LCHAD Deficiency: Nutrigenomics of Fatty Acid Oxidation Disorder.

International journal of molecular sciences2025 Oct 18

Mitochondrial long-chain fatty acid β-oxidation supplies energy to the heart, liver, and skeletal muscle. Impairment of this process due to a block at the step catalyzed by long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) leads to bioenergetic failure, manifesting as hypoglycemia, recurrent rhabdomyolysis, cardiomyopathy, and hepatic dysfunction. Accumulation of toxic intermediates-long-chain 3-hydroxyacyl-CoAs and the corresponding 3-hydroxyacylcarnitines-contributes to pigmentary retinopathy and peripheral neuropathy. Early diagnosis and careful dietary management can reduce life-threatening decompensation in childhood and improve survival into adulthood. This review examines the genetics of human LCHAD deficiency, describes its multisystem complications, and outlines nutritional strategies used to bypass the enzymatic block. We also explore nutrigenomic signals elicited by dietary treatment in LCHAD deficiency.

#5

Characterizing Long-Chain 3-Hydroxy-Acyl-CoA Dehydrogenase Deficiency (LCHADD) Chorioretinopathy Using OCT and OCTA.

Investigative ophthalmology &amp; visual science2025 Sep 02

To characterize structural and microvascular alterations in chorioretinopathy in patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD) using optical coherence tomography (OCT) and OCT angiography (OCTA). Thirty-six eyes from 19 patients with LCHADD were evaluated and categorized into six stages of increasing severity. Avanti and Solix OCTA devices were used to scan acquire 3 × 3-mm macular scans of the eyes. The thicknesses of the inner retina, outer retina, and choroid were measured from OCT scans. Vessel density (VD) and nonperfusion area (NPA) were calculated from en face projection-resolved OCTA in four slabs: the superficial vascular complex, intermediate capillary plexus, deep capillary plexus (DCP), and choriocapillaris (CC). The correlations (Spearman's rank) between these structural and angiographic metrics and traditional clinical metrics (the LCHADD severity, best-corrected visual acuity [BCVA], and plasma acylcarnitines) were investigated. Pronounced thinning in the outer retina and choroid was observed, along with marked VD loss and increased NPA in the DCP and CC at severe stages. The outer retinal and choroidal thicknesses correlated with all traditional clinical metrics, VD/NPA in the DCP and CC were significantly correlated with the LCHADD severity and BCVA, and only VD/NPA in the CC were associated with plasma acylcarnitines. Combined OCT/OCTA imaging enables visualization and quantification of structural and microvascular alterations in the chorioretinal slabs at different stages of LCHADD. The pathology of LCHADD impacts the deeper retinal plexuses more than the inner layers. OCT and OCTA parameters may improve understanding of the pathological changes in LCHADD chorioretinopathy and aid in monitoring disease progression.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC56 artigos no totalmostrando 107

2026

MR Neurography in Children and Adolescents: Multiparametric Assessment of Peripheral Nerve Involvement in Long-chain Fatty Acid Oxidation Disorders.

Investigative radiology
2026

Elamipretide Improves Mitochondrial Function in Mitochondrial Trifunctional Protein-Deficient Mice and Human Fibroblasts.

Journal of inherited metabolic disease
2025

The Hidden Metabolic Threat: A Case of Fatty Acid Oxidation Disorder Masquerading as Viral Myocarditis.

Cureus
2025

How Genes Meet Diet in LCHAD Deficiency: Nutrigenomics of Fatty Acid Oxidation Disorder.

International journal of molecular sciences
2025

Characterizing Long-Chain 3-Hydroxy-Acyl-CoA Dehydrogenase Deficiency (LCHADD) Chorioretinopathy Using OCT and OCTA.

Investigative ophthalmology &amp; visual science
2026

Early-Onset Sensorimotor Axonal Neuropathy as Sole Manifestation of HADHA-Related Disorder/ Mitochondrial Trifunctional Protein Defect.

Journal of child neurology
2025

Mitochondrial Trifunctional Protein Deficiency due to HADHA Variants Masquerading as Charcot-Marie-Tooth Disease.

Journal of the peripheral nervous system : JPNS
2025

Plasma Metabolomics, Lipidomics, and Acylcarnitines Are Associated With Vision and Genotype but Not With Dietary Intake in Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHADD).

Journal of inherited metabolic disease
2025

A pharmacological profile of triheptanoin for the treatment of long-chain fatty acid oxidation disorders.

Expert review of clinical pharmacology
2025

[LCHADD-associated chorioretinopathy (case study)].

Vestnik oftalmologii
2025

Pigmentary chorioretinopathy due to long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHAD): a case report with long-term follow-up.

Archivos de la Sociedad Espanola de Oftalmologia
2025

Cardiomyopathy in a c.1528G>C Hadha mouse is associated with cardiac tissue lipotoxicity and altered cardiolipin species.

Journal of lipid research
2025

Triheptanoin use for severe neonatal cardiomyopathy secondary to mitochondrial trifunctional protein deficiency: a first report.

Cardiology in the young
2025

Mitochondrial trifunctional protein deficiency caused by a deep intronic deletion leading to aberrant splicing.

JIMD reports
2024

Peripheral Neuropathy in Mitochondrial Trifunctional Protein Deficiency due to a Variant in HADHA Gene.

Iranian journal of pathology
2025

Periodic Paralysis in a Child With Thermosensitive Mitochondrial Trifunctional Protein Deficiency.

American journal of medical genetics. Part A
2024

iPSC-Derived LCHADD Retinal Pigment Epithelial Cells Are Susceptible to Lipid Peroxidation and Rescued by Transfection of a Wildtype AAV-HADHA Vector.

Investigative ophthalmology &amp; visual science
2024

Mitochondrial bioenergetics and cardiolipin remodeling abnormalities in mitochondrial trifunctional protein deficiency.

JCI insight
2024

D-Bifunctional Protein Deficiency Diagnosis-A Challenge in Low Resource Settings: Case Report and Review of the Literature.

International journal of molecular sciences
2024

Early diagnosis and treatment by newborn screening (NBS) or family history is associated with improved visual outcomes for long-chain 3-hydroxyacylCoA dehydrogenase deficiency (LCHADD) chorioretinopathy.

Journal of inherited metabolic disease
2024

Cardiac phenotype in adolescents and young adults with long-chain 3-hydroxyacyl CoA dehydrogenase (LCHAD) deficiency.

Genetics in medicine : official journal of the American College of Medical Genetics
2024

TFP/LCHAD Deficiency Due to HADHA Gene Mutation.

Clinical pediatrics
2024

Impact of newborn screening for fatty acid oxidation disorders on neurological outcome: A Belgian retrospective and multicentric study.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2024

Tracer-based lipidomics enables the discovery of disease-specific candidate biomarkers in mitochondrial β-oxidation disorders.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2024

A proposal for an updated staging system for LCHADD retinopathy.

Ophthalmic genetics
2024

Neurological outcome in long-chain hydroxy fatty acid oxidation disorders.

Annals of clinical and translational neurology
2024

Psychosocial issues and coping strategies in families affected by long-chain fatty acid oxidation disorders.

JIMD reports
2023

A G1528C Hadha knock-in mouse model recapitulates aspects of human clinical phenotypes for long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.

Communications biology
2023

An Autopsy Analysis of a Patient With Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency Caused by Compound Heterozygous HADHA Gene Mutations.

The American journal of forensic medicine and pathology
2023

Case report: Mitochondrial trifunctional protein deficiency caused by HADHB gene mutation (c.1175C>T) characterized by higher brain dysfunction followed by neuropathy, presented gadolinium enhancement on brain imaging in an adult patient.

Frontiers in neurology
2023

Successful management of rhabdomyolysis with triheptanoin in a child with severe long-chain 3-hydroxyacyl-coenzyme A dehydrogenase (LCHAD) deficiency.

Neuromuscular disorders : NMD
2023

'Small' data, isolated populations, and new categories of rare diseases in Finland and Poland.

Anthropology &amp; medicine
2022

[Thermosensibility and mitochondrial trifunctional protein deficiencies].

Medecine sciences : M/S
2022

Recurrent metabolic alkalosis following ketone body treatment of adult mitochondrial trifunctional protein deficiency: A case report.

JIMD reports
2022

Effectiveness of Robotic-Assisted Gait Training and Aquatic Physical Therapy in a Child With Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency: A Case Report.

Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association
2022

A 24-Year-Old Woman Presenting in the Third Trimester of Pregnancy with Nausea, Vomiting, and Abdominal Pain and Diagnosed with Acute Fatty Liver of Pregnancy.

The American journal of case reports
2022

Genetic diversity in Kashubs: the regional increase in the frequency of several disease-causing variants.

Journal of applied genetics
2022

ECHS1 deficiency and its biochemical and clinical phenotype.

American journal of medical genetics. Part A
2022

Outcomes and genotype correlations in patients with mitochondrial trifunctional protein or isolated long chain 3-hydroxyacyl-CoA dehydrogenase deficiency enrolled in the IBEM-IS database.

Molecular genetics and metabolism reports
2022

Reversible sensory neuropathy in mitochondrial trifunctional protein deficiency.

JIMD reports
2022

Thermo-sensitive mitochondrial trifunctional protein deficiency presenting with episodic myopathy.

Journal of inherited metabolic disease
2022

Genetic, biochemical, and clinical spectrum of patients with mitochondrial trifunctional protein deficiency identified after the introduction of newborn screening in the Netherlands.

Journal of inherited metabolic disease
2022

Paternal uniparental disomy of chromosome 2 resulting in a concurrent presentation of Crigler-Najjar syndrome type I and long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.

American journal of medical genetics. Part A
2022

A Case of ECHS1 Deficiency with Severe Encephalopathy and Status Epilepticus after a Propofol Sedation: Case Report.

Neuropediatrics
2021

Mitochondrial trifunctional protein deficiency as a polyneuropathy etiology in childhood.

The Turkish journal of pediatrics
2022

Analysis of a family with mitochondrial trifunctional protein deficiency caused by HADHA gene mutations.

Molecular medicine reports
2021

Charcot-Marie-Tooth Disease With Episodic Rhabdomyolysis Due to Two Novel Mutations in the β Subunit of Mitochondrial Trifunctional Protein and Effective Response to Modified Diet Therapy.

Frontiers in neurology
2021

Impact of Newborn Screening and Early Dietary Management on Clinical Outcome of Patients with Long Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency and Medium Chain Acyl-CoA Dehydrogenase Deficiency-A Retrospective Nationwide Study.

Nutrients
2021

Hypoparathyroidism, neutropenia and nephrotic syndrome in a patient with mitochondrial trifunctional protein deficiency: A case report and review of the literature.

European journal of medical genetics
2021

Retinitis pigmentosa as a clinical presentation of LCHAD deficiency: A clinical case and review of the literature.

Archivos de la Sociedad Espanola de Oftalmologia
2020

A Rare Presentation of Cardiomyopathy in Pregnancy.

JACC. Case reports
2021

Different Lipid Signature in Fibroblasts of Long-Chain Fatty Acid Oxidation Disorders.

Cells
2021

MTP deficiency caused by HADHB mutations: Pathophysiology and clinical manifestations.

Molecular genetics and metabolism
2021

The spectrum of peripheral neuropathy in disorders of the mitochondrial trifunctional protein.

Journal of inherited metabolic disease
2021

Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency and progressive retinopathy: one case report followed by ERGs, VEPs, EOG over a 17-year period.

Documenta ophthalmologica. Advances in ophthalmology
2021

Retained visual function in a subset of patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD).

Ophthalmic genetics
2020

Using Mitochondrial Trifunctional Protein Deficiency to Understand Maternal Health.

Journal of cellular signaling
2020

Effects of fasting, feeding and exercise on plasma acylcarnitines among subjects with CPT2D, VLCADD and LCHADD/TFPD.

Molecular genetics and metabolism
2020

Multisystem involvement in Chinese patients with neuromyopathic phenotype of mitochondrial trifunctional protein deficiency.

Chinese medical journal
2020

Efficacy of bezafibrate in two patients with mitochondrial trifunctional protein deficiency.

Molecular genetics and metabolism reports
2020

Novel HADHB mutations in a patient with mitochondrial trifunctional protein deficiency.

Human genome variation
2020

Sensory neuronopathy as a major clinical feature of mitochondrial trifunctional protein deficiency in adults.

Revue neurologique
2019

Evaluation of earlier versus later dietary management in long-chain 3-hydroxyacyl-CoA dehydrogenase or mitochondrial trifunctional protein deficiency: a systematic review.

Orphanet journal of rare diseases
2019

TFPa/HADHA is required for fatty acid beta-oxidation and cardiolipin re-modeling in human cardiomyocytes.

Nature communications
2019

Identification and functional characterization of mutations within HADHB associated with mitochondrial trifunctional protein deficiency.

Mitochondrion
2022

CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY.

Retinal cases &amp; brief reports
2019

Serial fatty acid profiles in a preterm infant with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.

Pediatrics international : official journal of the Japan Pediatric Society
2019

Impaired Fat Oxidation During Exercise in Long-Chain Acyl-CoA Dehydrogenase Deficiency Patients and Effect of IV-Glucose.

The Journal of clinical endocrinology and metabolism
2019

Evaluation of Metabolic Defects in Fatty Acid Oxidation Using Peripheral Blood Mononuclear Cells Loaded with Deuterium-Labeled Fatty Acids.

Disease markers
2019

Collapsing glomerulopathy in a child with LCHAD deficiency: a rare association.

CEN case reports
2019

HADHA and HADHB gene associated phenotypes - Identification of rare variants in a patient cohort by Next Generation Sequencing.

Molecular and cellular probes
2018

Fatal pitfalls in newborn screening for mitochondrial trifunctional protein (MTP)/long-chain 3-Hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency.

Orphanet journal of rare diseases
2018

HADHB mutations cause infantile-onset axonal Charcot-Marie-Tooth disease: A report of two cases.

Clinical neuropathology
2018

Cryo-EM structure of human mitochondrial trifunctional protein.

Proceedings of the National Academy of Sciences of the United States of America
2017

Trifunctional Protein Deficiency Due to HADHB Mutations Is a Multisystem, β-Oxidation Disorder.

Archives of Iranian medicine
2018

Regulation of mitochondrial trifunctional protein modulates nonalcoholic fatty liver disease in mice.

Journal of lipid research
2018

Retinal Dystrophy in Long-Chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency.

Ophthalmology. Retina
2018

Mitochondrial Trifunctional Protein Deficiency: Severe Cardiomyopathy and Cardiac Transplantation.

JIMD reports
2017

Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.

Journal of inherited metabolic disease
2017

Energy exchangers with LCT as a precision method for diet control in LCHADD.

Advances in clinical and experimental medicine : official organ Wroclaw Medical University
2018

Peripheral Neuropathy, Episodic Rhabdomyolysis, and Hypoparathyroidism in a Patient with Mitochondrial Trifunctional Protein Deficiency.

JIMD reports
2017

Clinical and molecular investigation of 14 Japanese patients with complete TFP deficiency: a comparison with Caucasian cases.

Journal of human genetics
2017

Pharmacological inhibition of carnitine palmitoyltransferase 1 restores mitochondrial oxidative phosphorylation in human trifunctional protein deficient fibroblasts.

Biochimica et biophysica acta. Molecular basis of disease
2019

RETINAL PHENOTYPE IN A CASE OF LCHAD/TFP DEFICIENCY WITH LATE-STAGE DIAGNOSIS.

Retinal cases &amp; brief reports
2017

Clinical course and cardiovascular outcomes in patients with the long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency.

Cardiology journal
2017

[Mitochondrial trifunctional protein deficiency: an adult patient with similar progress to Charcot-Marie-Tooth disease].

Rinsho shinkeigaku = Clinical neurology
2017

Identification of a Novel HADHB Gene Mutation in an Iranian Patient with Mitochondrial Trifunctional Protein Deficiency.

Archives of Iranian medicine
2016

An Unusual Case of LCHAD Deficiency Presenting With a Clinical Picture of Hemophagocytic Lymphohistiocytosis: Secondary HLH or Coincidence?

Journal of pediatric hematology/oncology
2017

MULTIMODAL IMAGING AND ELECTRORETINOGRAPHY IN LONG-CHAIN 3-HYDROXYACYL COENZYME A DEHYDROGENASE DEFICIENCY.

Retinal cases &amp; brief reports
2016

Characterization of Chorioretinopathy Associated with Mitochondrial Trifunctional Protein Disorders: Long-Term Follow-up of 21 Cases.

Ophthalmology
2016

Most patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency develop pathological or subnormal retinal function.

Acta paediatrica (Oslo, Norway : 1992)
2016

Disturbance of mitochondrial functions provoked by the major long-chain 3-hydroxylated fatty acids accumulating in MTP and LCHAD deficiencies in skeletal muscle.

Toxicology in vitro : an international journal published in association with BIBRA
2016

[Variation of long-chain 3-hydroxyacyl CoA dehydrogenase DNA methylated modification and correlation with gene mRNA expression of early-onset preeclampsia, HELLP syndrome and antiphospholipid syndrome in trophoblast cells of placenta].

Zhonghua fu chan ke za zhi
2016

A fetus with mitochondrial trifunctional protein deficiency: Elevation of 3-OH-acylcarnitines in amniotic fluid functionally assured the genetic diagnosis.

Molecular genetics and metabolism reports
2016

Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: A case report.

Archivos de la Sociedad Espanola de Oftalmologia
2016

Earlier diagnosis and strict diets improve the survival rate and clinical course of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.

Acta paediatrica (Oslo, Norway : 1992)
2015

[Variation of long-chain 3-hydroxyacyl-CoA dehydrogenase DNA methylation in placenta of different preeclampsia-like mouse models].

Zhonghua fu chan ke za zhi
2016

Peripheral neuropathy in patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency - A follow-up EMG study of 12 patients.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2015

Mitochondrial trifunctional protein deficiency due to HADHB gene mutation in a Chinese family.

Molecular genetics and metabolism reports
2015

Deregulation of mitochondrial functions provoked by long-chain fatty acid accumulating in long-chain 3-hydroxyacyl-CoA dehydrogenase and mitochondrial permeability transition deficiencies in rat heart--mitochondrial permeability transition pore opening as a potential contributing pathomechanism of cardiac alterations in these disorders.

The FEBS journal
2015

Noncompaction in mitochondrial trifunctional protein deficiency due to a HADHB mutation.

European journal of pediatrics
2016

Mitochondrial trifunctional protein deficiency in human cultured fibroblasts: effects of bezafibrate.

Journal of inherited metabolic disease
2015

Fetal left ventricular noncompaction cardiomyopathy and fatal outcome due to complete deficiency of mitochondrial trifunctional protein.

European journal of pediatrics
2015

Clinical outcome, biochemical and therapeutic follow-up in 14 Austrian patients with Long-Chain 3-Hydroxy Acyl CoA Dehydrogenase Deficiency (LCHADD).

Orphanet journal of rare diseases
2015

[The changes of LCHAD in preeclampsia with different clinical features and the correlation with NADPH P47-phox, p38MAPK-α, COX-2 and serum FFA and TG].

Zhonghua fu chan ke za zhi
2015

[Expression of long chain fatty acid oxidase in maternal and fetal tissues in preeclampsia-like mouse model in mid-gestation].

Zhonghua yi xue za zhi
2015

Uncoupling, metabolic inhibition and induction of mitochondrial permeability transition in rat liver mitochondria caused by the major long-chain hydroxyl monocarboxylic fatty acids accumulating in LCHAD deficiency.

Biochimica et biophysica acta

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Deficiência de proteína trifuncional mitocondrial.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Deficiência de proteína trifuncional mitocondrial

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Elamipretide Improves Mitochondrial Function in Mitochondrial Trifunctional Protein-Deficient Mice and Human Fibroblasts.
    Journal of inherited metabolic disease· 2026· PMID 41500837mais citado
  2. Early-Onset Sensorimotor Axonal Neuropathy as Sole Manifestation of HADHA-Related Disorder/ Mitochondrial Trifunctional Protein Defect.
    Journal of child neurology· 2026· PMID 40820380mais citado
  3. MR Neurography in Children and Adolescents: Multiparametric Assessment of Peripheral Nerve Involvement in Long-chain Fatty Acid Oxidation Disorders.
    Investigative radiology· 2026· PMID 41626767mais citado
  4. How Genes Meet Diet in LCHAD Deficiency: Nutrigenomics of Fatty Acid Oxidation Disorder.
    International journal of molecular sciences· 2025· PMID 41155433mais citado
  5. Characterizing Long-Chain 3-Hydroxy-Acyl-CoA Dehydrogenase Deficiency (LCHADD) Chorioretinopathy Using OCT and OCTA.
    Investigative ophthalmology &amp; visual science· 2025· PMID 40990866mais citado
  6. Corrigendum to: Mitochondrial bioenergetics and cardiolipin remodeling abnormalities in mitochondrial trifunctional protein deficiency.
    JCI Insight· 2026· PMID 41948938recente
  7. The Hidden Metabolic Threat: A Case of Fatty Acid Oxidation Disorder Masquerading as Viral Myocarditis.
    Cureus· 2025· PMID 41257106recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:746(Orphanet)
  2. MONDO:0012172(MONDO)
  3. GARD:3684(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q6881883(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Deficiência de proteína trifuncional mitocondrial
Compêndio · Raras BR

Deficiência de proteína trifuncional mitocondrial

ORPHA:746 · MONDO:0012172
Prevalência
Unknown
Casos
100 casos conhecidos
Herança
Autosomal recessive
CID-10
G71.3 · Miopatia mitocondrial não classificada em outra parte
CID-11
Ensaios
1 ativos
Início
Infancy, Neonatal
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C1969443
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades